Your browser doesn't support javascript.
loading
Cerebrospinal fluid and plasma ascorbate concentrations following subarachnoid haemorrhage.
Turner, Natasha; Farrow, Brodie; Betrie, Ashenafi H; Finnis, Mark E; Lankadeva, Yugeesh R; Sharman, Jeremy; Tan, Patrick; Abdelhamid, Yasmine Ali; Deane, Adam M; Plummer, Mark P.
Afiliação
  • Turner N; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
  • Farrow B; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
  • Betrie AH; Pre-clinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria 3052, Australia.
  • Finnis ME; Translational Neurodegeneration Laboratory, Florey Institute of Neuroscience and Mental Health, Health, Melbourne, Victoria 3052, Australia.
  • Lankadeva YR; Department of Critical Care, Melbourne Medical School, University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Sharman J; Intensive Care Unit Research, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.
  • Tan P; Pre-clinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria 3052, Australia.
  • Abdelhamid YA; Department of Critical Care, Melbourne Medical School, University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Deane AM; Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
  • Plummer MP; Department of Critical Care, Melbourne Medical School, University of Melbourne, Melbourne, Victoria 3010, Australia.
Crit Care Resusc ; 25(4): 175-181, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38234324
ABSTRACT

Background:

Ascorbate, the biologically active form of vitamin C, is the primary neural anti-oxidant. Ascorbate concentrations have never been quantified following aneurysmal subarachnoid haemorrhage (aSAH).

Objective:

To quantify plasma and cerebrospinal fluid (CSF) ascorbate concentrations in patients following SAH. Design Setting Participants Main Outcome

Measures:

Cohort study in which plasma and CSF ascorbate concentrations were measured longitudinally in 12 aSAH patients admitted to a quaternary referral intensive care unit and compared to one-off samples obtained from 20 pregnant women prior to delivery in a co-located obstetric hospital. Data are median [interquartile range] or median (95 % confidence intervals).

Results:

Forty-eight plasma samples were obtained from the 12 aSAH patients (eight females, age 62 [53-68] years). Eight participants with extra-ventricular drains provided 31 paired CSF-plasma samples. Single plasma and CSF samples were obtained from 20 pregnant women (age 35 [31-37] years). Initial plasma and CSF ascorbate concentrations post aSAH were less than half those in pregnant controls (plasma aSAH 31 [25-39] µmol/L vs. comparator 64 [59-77] µmol/L; P < 0.001 and CSF 116 [80-142] µmol/L vs. 252 [240-288] µmol/L; P < 0.001). Post aSAH there was a gradual reduction in the CSFplasma ascorbate ratio from ∼41 to ∼11. Six (50 %) patients developed vasospasm and CSF ascorbate concentrations were lower in these patients (vasospasm 61 (25, 97) vs. no vasospasm 110 (96, 125) µmol/L; P = 0.01).

Conclusion:

Post aSAH there is a marked reduction in CSF ascorbate concentration that is most prominent in those who develop vasospasm.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article